Navigation Links
Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint
Date:3/11/2011

CAMBRIDGE, Mass. and LONDON, March 11, 2011 /PRNewswire/ -- Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.  

Following preliminary review of the data, no new or unexpected treatment-related safety concerns have emerged during the DEFEND-1 study. Study investigators and regulatory agencies have been notified of the DEFEND-1 study outcome.

GSK will continue to explore additional dosing regimens to inform decisions about the future clinical development programme for otelixizumab.  New recruitment and dosing in the DEFEND-2 study, the ongoing confirmatory Phase 3 study with a design similar to DEFEND-1, has been suspended pending review of the DEFEND-1 results.

"While we are disappointed in the DEFEND-1 results of otelixizumab, we remain committed to the development and commercialization of the candidates in our pipeline, each of which has a distinct mechanism and target for correcting abnormal immune responses," said Douglas J. Ringler, VMD, President and Chief Executive Officer of Tolerx. "Our immunotherapy candidates represent some of the latest scientific advances in harnessing the immune system for therapeutic benefit, including TRX518 which is a showpiece of our pipeline as an immunotherapy to treat cancer."

"Clearly these are disappointing data, but we are committed to working with Tolerx to better understand the results of this study and determine the way forward," said Jackie Parkin, Medicines Development Leader, GlaxoSmithKline.

Tolerx Pipeline

In addition to otelixizumab, Tolerx has four product candidates in various stages of development, and each candidate is based on Tolerx's immunology expertise in understanding how therapies can be designed
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody
2. Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
3. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
4. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
5. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
6. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
7. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
8. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
9. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
10. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
11. GlaxoSmithKline Wins Environmental Stewardship Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... CHENGDU, China , Aug. 28, 2014 /PRNewswire/ ... TPI ), a pharmaceutical company that specializes ... branded generics and active pharmaceutical ingredients (API) today ... the Company,s Qionglai Facility (QLF). ... Manufacturing Practice (GMP) dataset for China Food & ...
(Date:8/28/2014)... SALT LAKE CITY , Aug. 28, 2014 /PRNewswire-iReach/ ... in 2000 by service academy graduates, has published a ... its concentrated, three-day Leadership Excellence Course . In ... the  Leadership Excellence Course to Albuquerque , ... Tucson . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
(Date:8/28/2014)... Aug. 28, 2014 Nonin Medical, Inc., the ... noninvasive medical monitoring, today announced that the Food and ... OEM/eHealth finger pulse oximeter for use in ... plugs into a telemedicine hub or kiosk through a ... in pediatric to adult patients. The Model 3231 received ...
Breaking Medicine Technology:TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... N.J., May 03, 2007 /PRNewswire-FirstCall/ --,Alpharma ... pharmaceutical company,through its Pharmaceuticals Division, this ... study of its investigational,abuse-deterrent, extended-release opioid ... the American Pain Society in Washington, ...
... /PRNewswire-FirstCall/ --,Genelabs Technologies, Inc. announced today that ... International Conference on Antiviral,Research being held in ... virus (HCV) polymerase inhibitor,discovered by Genelabs. , ... D. Roberts,Ph.D., Director of Medicinal Chemistry at ...
Cached Medicine Technology:Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 2Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 3Alpharma Presents Positive Pharmacokinetic Study Results of Its,Investigational Abuse-Deterrent, Extended-Release Opioid 4Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 2Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting 3
(Date:8/29/2014)... Sansego is an online ... online community, and a range of personalized coaching services. ... way to professional athletes. Crowie has brought together a ... him throughout the majority of his triathlon career. Now, ... triathlon public. , Sansego provides the following:, ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 RBS Reputation Management ... Scam Book. The service is to help those individuals ... against them on Scam Book. The service would push down ... make Scam Book complaints fully invisible on Google. , ... , On being asked how company can provide guarantee ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 "After ... people who don’t stand very often, I decided that there ... longer periods during the day," said a concerned inventor from ... can’t stand for long periods. It builds endurance and keeps ... promote better health. Easy to use and producible in design ...
(Date:8/29/2014)... Only a handful of CPR and basic life ... which are consistent with recent health guidelines, according ... Medicine Australasia , the journal for the Australasian ... recognition and treatment of sudden cardiac arrest are ... of Turkish emergency medicine specialists put together the ...
(Date:8/29/2014)... Miami, Florida (PRWEB) August 29, 2014 ... is pleased to introduce its new Fresh Vegetarian meal ... nutritionally balanced fresh meals, the new menu is designed ... enhance their vegetarian lifestyle. , Responding to ... estimated to be a multi-billion dollar market (Forbes) with ...
Breaking Medicine News(10 mins):Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 2Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 3Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3
... by the placenta may damage blood vessels in women ... pregnancy linked to life-threatening increases in high blood pressure ... recognized that substances called "microparticles" released by the placenta ... Medicine, led by Seth Guller, sought to detect whether ...
... at the University of British Columbia have discovered new ... cancer. // ,The research conducted by UBC stem ... podocalyxin – which the researchers had previously shown to ... the shape and adhesive quality of tumour cells, affecting ...
... with facts and figures has shown the dangerous increase in ... years//. The number of children below five years of age, ... fold between 1985 and 2004. ,Type 1 diabetes ... childhood as opposed to Type 2 diabetes, which develops much ...
... Space Administration (NASA) has revealed that the sunscreen of ... 1990s. ,Aerosols are tiny particles suspended in ... storms, forest and grassland fires, living vegetation, and sea ... the Earth's surface immediately below them. ...
... out strongly against the use of sunbeds or tanning beds, ... to the Working Group on artificial UV light and skin ... persons who use these tanning beds in order to avoid ... higher risks of developing melanoma, the most dreaded skin cancer. ...
... organizations in Maine criticized the anti-fluoride campaigns made by a ... believe the false information and alter their water treatment policies. ... for Disease Control had confirmed in a news conference that ... in fighting tooth decay. ,This announcement has ...
Cached Medicine News:Health News:New Non-toxic Therapies for Breast, Ovarian Cancers 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: